

REFERENCES

- Aarons L. Population pharmacokinetics: theory and practice. *Br J. clin Pharmacol.* 1991; **32**: 669-70.
- Ahmed MT., Jehanli Towfiq Arafat, Munzir al-Shami. Determination of captopril in human blood by an enzyme-linked immunosorbent assay. *J. Pharm. Pharmacol.* 1996; **48**: 914-917.
- Allen JE. Drug monograph: oral angiotensin-converting enzyme inhibitors. Oak Brook, IL: *University Health System Consortium*. 1992.
- Anderson S, Hauck WW. A new procedure for testing equivalence in comparative bioavailability and other clinical trials. *Commun. Statist. Theor. Meth.* 1983; **12**: 2663-2692.
- Arroyo C., Lopez-Calull C., Garcia-Capdevila L., Gich I., Barbanoj M., Bonal J. Determination of captopril in plasma by high-performance liquid chromatography for pharmacokinetic studies. *J Chromatogr B Appl.* 1997; **668**: 339-44.
- Barry LT., Maria TO., Jay NC. Angiotensin converting enzyme inhibitors in congestive heart failure. Overview in comparison of captopril and enalapril. *The American Journal of Medicine.* 1986; **81**(suppl 4C): 36-39.
- Bathala MS., Weinstein SH., Meeker Jr. FS., Singhvi SM., Migdalof BH. Quantitative determination of captopril and its disulphide metabolites in plasma by gas-chromatography. *Journal of Pharmaceutical Sciences.* 1984; **73**: 340-344.
- Bertram G. Katzung. Basic and Clinical Pharmacology, 4th. Edition, p.135, 1989.
- Bjorck S., Nyberg G., Mulee H., Granerus G., Herlitz H., *et al.* Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. *British Medical Journal.* 1986;**293**: 471-474.

- Brogden RN., Peter A. Todd, Eugene M. Sorkin. Captopril: An Update of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Use in Hypertension and Congestive Heart Failure. *Drugs*. 1988; **36**: 540-600.
- Burnier M., Biollaz J. Pharmacokinetic optimization of angiotensin-converting enzyme (ACE) inhibitor therapy. *Clin Pharmacokinet*. 1992; **22**: 375-84.
- Catherine VG. Oral angiotensin-converting enzyme inhibitors (Formulary review) *Am J Health -Syst Pharm*. 1997; **54**: 2689-2703.
- Chalmers D., Dombey, Lawson DH., Postmarketing surveillance of captopril for hypertension: a preliminary report. *Br. J. of Clinical Practice*. 1987; **24**: 343-349.
- Cody RJ. Optimising ACE inhibitor therapy of congestive heart failure: insights from pharmacodynamic studies. *Clin pharmacokinet*. 1993; **24**:59-70.
- Cohen AI., Devlin RG., Ivashkiv E., Funke PT., McCormick T. Determination of captopril in human blood and urine by GLC-selected-ion monitoring mass spectrometry after oral coadministration with its isotopomer. *J. Pharm Sci*. 1982; **71**: 1251-6.
- Cohn JN. New concepts in the mechanisms and treatment of congestive heart failure. *Am J Cardiol*. 1985; **55**:1-2.
- Covit AB., Kubo SH., Feldschuh J., Laragh JH. Factors influencing glomerular filtration rate in patients with congestive heart failure. *Journal of American College of Cardiology*. 1985;**5**:529
- Creasey WA., Funkee PT. Mc Kinstry DN., Sugermann AA. Pharmacokinetics of captopril in elderly healthy male volunteers. *Journal of Clinical Pharmacology*. 1986; **26**: 264-268.

- Cushman DW., Wang FL., Fung WC., Harvey CM., DeForrest JM. Differentiation of angiotensin-converting enzyme (ACE) inhibitors by their selective inhibition of ACE physiologically important target organs. *American Journal of Hypertension*. 1989; **2**: 294-306.
- Davidson D., Stalcup SA., Mellins RB., Captopril administration to the pregnant guinea pig inhibits fetal angiotensin converting enzyme activity. *Pediatric Research*. 1981; **15**:658.
- Devlin RG., Fleiss PM. Captopril in human blood and breast milk. *Journal of Clinical Pharmacology*. 1981; **21**: 110-113.
- Drummer OH., Jarrot B. Captopril disulphide conjugates may act as prodrugs: disposition of the disulphide dimer of captopril in the rat. *Biochem. Pharmacology*. 1984; **33**: 3567-3571.
- Drummer OH., Jarrot B. The disposition and metabolism of captopril. *Medicinal Research Reviews*. 1986; **6**: 75-97.
- Drummer OH., Jarrot B., Louis WJ. Combined gas chromatography-mass spectrometric procedure for the measurement of captopril and sulphur-conjugated metabolites of captopril in plasma and urine. *Journal of Chromatography*. 1984; **305**: 83-93.
- Drummer OH., Kourtis S., Jarrott B. Inhibition of angiotensin converting enzyme by metabolites of captopril. *Clinical and Experimental Pharmacology and Physiology*. 1985; **9**(suppl.): 12-13.
- Duchin KL, McKinstry DN, Cohen AI, Migdalof BH. Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases. *Clin. Pharmacokinet*. 1988; **14**: 241-59.
- Duchin KL., Singhvi SM., Willard DA., Migdalof BH., McKinstry DN. Captopril kinetics. *Clinical Pharmacology and Therapeutics*. 1982b; **31**: 452-458.

Duchin KL., Singhvi SM., Willard DA. Renal handling of captopril in normal volunteers. *Clin Pharmacol Ther.* 1982; **31**:221.

Edwards IR., Coulter DM., Beasley DMG., Macintosh D. Captopril: 4 years of post marketing surveillance of all patients in New Zealand. *British Journal of Clinical Pharmacology.* 1987;**23**: 529-536.

Edward B., Stanislaw S., Jozef D., Mariusz Stepień. Application of 2-halopyridinium salts as ultraviolet derivation reagents and solid-phase extraction for determination of captopril in human plasma by high-performance liquid chromatography. *Journal of Chromatography B.* 1996; **681**:283-289.

Ferreira SH. A bradykinin-potentiating factor (BPF) present in the venom of *Bothrops jararaca*. *British Journal of Pharmacology and Chemotherapy.* 1965; **24**: 164-169.

Ferreira SH., Bartelt DC., Greene LJ. Isolation of bradykinin-potentiating peptides from *Bothrops jararaca* venom. *Hautarzt.* 1969; **20(11)**: 2583-93.

Frampton JE., Peters DH. Ramipril: an updated review of its therapeutic use in essential hypertension and heart failure. *Drugs.* 1995; **49**:440-66.

Francoise Bressolle, Maguy Bromet-Petit, Michel Audran. Validation of liquid chromatographic and gas chromatographic methods: Applications to pharmacokinetics. *Journal of Chromatography B.* 1996; **686**: 3-10.

Franklin ME., Addison RS., Baker PV., Hooper WD. Improved analytical procedure for the measurement of captopril in human plasma by gas chromatography-mass spectrometry and its application to pharmacokinetic studies. *Journal of Chromatography B.* 1998; **705**: 47-54.

Frewin DB., *et al.* Is captopril effective in controlling blood pressure when administered once daily ? An assessment using 24-h ambulatory blood pressure monitoring. *Eur J. Clin Pharmacol.* 1986; **36**: 11-15.

- Funke PT., Ivashkiv E., Malley MF., Cohen AI. Gas chromatography/selected-ion monitoring mass spectrometric determination of captopril in human blood. *Analytical Chemistry*. 1980; **52**: 1086-1089.
- Garg R, Yusuf S, for the collaborative Group on ACE inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. *JAMA*. 1995; **273**:1450-6.
- Giudicelli JF., Chaignon M., Richer C., Giroux B., Guedon J. Influence of chronic renal failure on captopril pharmacokinetics and clinical and biological effects in hypertensive patients. *Br J. clin Pharmacol*. 1984; **18**: 749-758.
- Goldsmith SR., Francis GS., Cowley AW., Levine TB., Cohn JN. Increase plasma arginine vasopressin in patients with congestive heart failure. *J Am. Coll Cardiol*. 1983; **1**: 1385-1390.
- Groel JT., Tadross SS., Dreslinski GR., Jenkins AC. Long term antihypertensive therapy with captopril. *Hypertension* 5 (Suppl III). 1983;145-151
- Hans Jorg Leis, Margot Leis, Walter Welz, Ernst Malle. Determination of captopril in human blood by gas chromatography-negative-ion chemical ionization mass spectrometry with [$^{18}\text{O}_4$]captopril as internal standard. *Journal of Chromatography*. 1990; **529**: 299-306.
- Hauck WW, Anderson S. Types of bioequivalence and related statistical considerations. *International Journal of Clinical Pharmacology, Therapy and Toxicology*. 1992; **30** (5): 181-187.
- Hauscke D., Steinijans VW., Diletti E. A distribution-free procedure for the statistical analysis of bioequivalence studies. *International Journal of Clin Pharmacol Ther Toxicol*. 1990; **28**: 72-78.
- Hayashi K., Miyamoto M., Sekine Y. Determination of captopril and its mixed disulphides in plasma and urine by high-performance liquid chromatography. *Journal of Chromatography*. 1985; **338**: 161-169.

Heald AF., and Ita CE., Distribution in rats of an inhibitor of angiotensin-converting enzyme, SQ14225, as studied by whole autoradiography and liquid scintillation counting.. *Pharmacologist* 1977;**19**:129.

Heel RC., Brogden RN., Speight TM. *et al.* Captopril: A preliminary review of its pharmacological properties and therapeutic efficacy. *Drugs*. 1980; **20**: 409-452.

Hercuelz A. Bioequivalence assessment and the conduct of bioequivalence trials: a European point of view. *European Journal of Drug Metabolism and Pharmacokinetics*. 1996; **21**: 149-152.

Hodsman GP., Isles CG., Murray GD., Usherwood TP., Webb DJ., Robertson JIS. Factors related to first dose hypotensive effect of captopril:prediction and treatment. *British Medical Journal*. 1983b; **286**: 832-834.

Horovitz ZP., ed. Angiotensin converting enzyme inhibitors: mechanisms of action and clinical implications. *Baltimore: Urban & Schwarzenberg*. 1981: 1-181.

Ivashkiv E., McKinstry DN., Cohen AI. Determination of total captopril in human plasma by gas chromatography-mass spectrometry with selected-ion monitoring after reduction disulfides. *Journal of Pharmaceutical Sciences*. 1984; **73**: 1113-1117.

Jankowski A., Skorek A., Krzyko K., Zarzycki PK., Ochocka RJ., Lamparczyk H. Captopril: determination in blood and pharmacokinetics after single oral dose. *Journal of Pharmaceutical & Biomedical Analysis*. 1995; **13**: 655-660.

Jarrott B., Anderson A., Hooper R., Louis WJ. High-performance liquid chromatographic analysis of captopril in plasma. *Journal of Pharmaceutical Sciences*. 1981a; **70**: 665-667.

Jenkins AC., Dreslinski GR., Tadros SS., Groel JT., Fand R. *et al.* Captopril in hypertension: seven years later. *Journal of Cardiovascular Pharmacology*. 1985a; **7** (suppl.): S96-S101.

- Jenkins AC., Dreslinski GR., Tadros SS., Groel JT., Fand R. *et al.* Captopril in hypertension: seven years later. *Journal of Cardiovascular Pharmacology*. 1985a; **7** (suppl.): S96-S101.
- Jenkins AC., Knill JR., Dreslinski GR. Captopril in the treatment of the elderly hypertensive patient. *Archives of Internal Medicine*. 1985b; **145**: 2029-2031.
- Kawahara Y., Hisaoka M., Yamazaki Y., Inage A., Morioka T. Determinations of captopril in blood and urine by high-performance liquid chromatography. *Chem Pharm Bull*. 1981; **5**: 97-110.
- Kelly JO., O'Malley K. Clinical pharmacokinetics of the newer ACE inhibitors. *Clin Pharmacokinetic*. 1990; **19**: 177-96.
- Kripalani KJ., Dean AV., Migdalof BH. Metabolism of captopril L-cysteine, a captopril metabolite, in rats and dogs. *Xenobiotica* 1983; **13**: 701-705.
- Kripalani KJ., McKinstry DN., Singhvi SM., Willard DA., Vukovich RA, Migdalof BH. Disposition of captopril in normal subjects. *J. Clin Pharmacol* 1980; **27**: 636-41.
- Kripalani KJ., Meeker Jr. FS., Dean AV., McKinstry DN., Migdalof B.H. Biotransformation of ¹⁴C-captopril in hypertensive patients and normal subjects. *Federation Proceedings*. 1980b; **39**: 307.
- Kubo SH., Cody RJ. Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors: a review. *Clinical Pharmacokinetics*. 1985; **10**: 377-391.
- Leonetti G, Cuspidi C. Choosing the right ACE inhibitor: a guide to selection. *Drugs*. 1995; **49**: 516-35.
- Levine TB., Francis GS., Goldsmith SR., Simon A., Cohn JN. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relationship to hemodynamic abnormalities in congestive heart failure. *Am J Cardiol*. 1982; **48**: 1659-1666.

MacKichan JJ., Comstock TJ. General pharmacokinetics Principles. In Taylor WJ., Diers Caviness, MH., eds. *A textbook for the clinical application of therapeutic drug monitoring*. Irving TX: Abbot Laboratories. 1986: 3-30.

Maeda T., Tanaka K., Kawameta W., Koma T., and Shindo H. Studies on the metabolism of a new antihypertensive agent. SQ14225 (captopril). I. Invitro studies on the binding to plasma protein and behaviour in blood. *The 99th Annual Meeting of the Pharmaceutical Society of Japan, Sapporo*. August 28-30, 1979.

Malaysian Guidelines For The Conduct of Bioavailability and Bioequivalence Studies. *Ministry of Health, Malaysia*, 2000.

Mantyla R., Mannisto PT., Vuorela A., Sundberg S., Ottoila P., Impairment of captopril bioavailability by concomitant food and antacid intake. *International Journal of Clinical Pharmacology, Therapy and Toxicology*. 1984; **22**: 626-629.

Martindale: The Extra Pharmacopoeia 30th Edition. 1993. Page 346.

Massana E., Barbanoj MJ., Moros C., Morte A., Gich I., Jane F. No Sex-related pharmacokinetic and pharmacodynamic differences of captopril. *Pharmacological Research*. 1997; **36**(1): 41-47.

Matsuki Y., Ito T., Fukuhara K., Ono H., Ohara N, *et al*. Determination of captopril in biological fluids by gas-liquid chromatography. *Journal of Chromatography*. 1980; **188**: 177-183.

Matsuki Y., Ito T., Fukuhara K., Nakamura T, Kimura M, *et al*. Determination of captopril and its disulphide in biological fluids. *Journal of Chromatography*. 1982; **239**: 585-594.

McKinstry DN., Kripalani KJ., Migdalof BH., Willard DA. The effects of repeated administration of captopril (CP) on its disposition in hypertensive patients. *Clinical Pharmacology and Therapeutics*. 1980; **27**: 270-271.

McKinstry DN., Singhvi SM., Kripalani KJ., Dreyfuss J., Willard DA. *et al.* Disposition and cardiovascular-endocrine effects of an orally active angiotensin-converting enzyme inhibitor, SQ 14,225, in normal subjects. *Clinical Pharmacology and Therapeutics*. 1978; **23**: 121-122.

Migdaloff BH., Singhvi SM., Kripalani KJ. Thin-layer radiochromatographic determination of captopril (SQ 14,225) and its disulfide dimer metabolite in blood. *J. Liq Chromatography*. 1980; **3**:857-65.

Muller HH., Overlack A., Heck I., Kolloch R., Stumpe KO. The influence of food intake on pharmacodynamics and plasma concentration of captopril. *Journal of hypertension*. 1985; **3**(suppl 2): S135-S136.

Nussberger J., Fleck E., Bharmann H *et al.* for the study group on Neurohormonal Regulation in Congestive heart Failure. Dose related effects of ACE inhibition in man: quinapril in patients with moderate congestive heart failure. *Eur Heart J*. 1994; **15** (suppl D): 113-22.

Ohman KP., Kagedal B., Larsson R., Karlberg BE., Pharmacokinetics of captopril and its effects on blood pressure during acute and chronic administration and in relation to food intake. *Journal of Cardiovascular Pharmacology*. 1985; **7**: S20-S24.

Olaf HD., Bevyn J., William JL. Combined gas chromatographic-mass spectrometric procedure for the measurement of captopril and sulfur-conjugated metabolites of captopril in plasma and urine. *Journal of Chromatography*. 1984; **305**:83-93.

Ondetti MA. Structure relationships of angiotensin-converting enzyme inhibitors to pharmacological activity. *Circulation*. 1988; **77**(suppl 1): 174-178.

Ondetti MA., Rubin B., Cushman DW. Design of specific inhibitors of angiotensin-converting enzyme: a new class of orally active antihypertensive agents. *Science*. 1977; **196**: 441-444.

Ondetti MA., Williams NJ., Sabo EF., *et al.* Angiotensin-converting enzyme inhibitors from the venom of *Bothrops jararaca*: isolation, elucidation of structure, and synthesis. *Biochemistry*. 1971; **10** (22): 4033-9.

Onoyama K., Hirakata H., Iseki K. Fujimi S., Omae T., Kobayashi M., Kawahara Y. Blood concentration and urinary excretion of captopril (SQ 14,225) in patients with chronic renal failure. *Hypertension* 1981; **3**: 456-9.

Opsahl JA., Abraham PA., Keane WF. Renal effect of angiotensin converting enzyme inhibitors: nondiabetic chronic renal disease. *Cardiovascular Drugs and Therapy*. 1990;**4**:221-228.

Park BK., Grabowski PS., Yeung JHK., Breckenridge AM. Drug protein conjugates I. A study of the covalent binding of captopril to plasma proteins in the rat. *Biochemical pharmacology*. 1982; **31**: 1755-1760.

Patnaik R., Lesko LJ., Chan K., Williams RL. Bioequivalence assessment of generic drugs: an American point of view. *Eur. J of Drug Metabolism Pharmacokinetics*. 1996; **21**: 159-164.

Pereira CM., Tam YK., Collins-Nakai RL., Ng. P. Simplified determination of captopril in plasma by high-performance liquid chromatography. *Journal of Chromatography*. 1988; **425**: 208-213.

Pidgen A.W. Statistical aspects of bioequivalence-a review. *Xenobiotica*. 1992; **22**: 881-893.

Pipkin FB., Symonds EM., and Turner SR. The effect of captopril (SQ14225) upon mother and fetus in the chronically cannulated ewe and in the pregnant rabbit. *Journal of Physiology* .1982; **323**: 415-422.

Rahmat J., Gelfand RL., Gelfand MC., Winchester JF., Schreiner GE, *et al.* Captopril-associated cholestatic jaundice. *Annals of Internal Medicine*. 1985; **102**: 56-58.

- Richer C, Giroux B, Plouin PF, Maarek B, Giudicelli F. Captopril: pharmacokinetics, antihypertensive and biological effects in hypertensive patients. *Br J. Clin Pharmacol.* 1984; **17**: 243-50.
- Robert DiBianco. Angiotensin-converting enzyme inhibition: Unique and effective therapy for hypertension and congestive heart failure. *Postgraduate Medicine.* 1985; **78**: 229-248.
- Robert DiBianco. Adverse reactions with angiotensin converting enzyme (ACE) inhibitors. *Medical Toxicology.* 1986; **1**: 122-141.
- Robert J.K., Jan V., Frits Moolenaar, Dick de Zeewuw, Dirk K.F.M. Bioanalysis of captopril: two sensitive high-performance liquid chromatographic methods with pre- or postcolumn fluorescent labeling. *Journal of Chromatography B.* 1997; **693**: 181-189.
- Romankiewicz JA., Brogden RN., Heel RC., Speight TM., Avery GS. Captopril: an update review of its pharmacological properties and therapeutic efficacy in congestive heart failure. *Drugs.* 1983; **25**: 6-40.
- Salveti A., Pedrinelli R., Magagna A., Abdel Haq B., Graziadel L., *et al.* Influence of food on acute and chronic effects of captopril in essential hypertensive patients. *Journal of Cardiovascular Pharmacology.* 1985; **7**: S25-S29.
- Schuirman DJ. A comparison of two one-sided test procedure and the power approach for assessing the bioequivalence or average bioavailability. *Journal Pharmacokinetic Biopharm.* 1987; **15**: 657-680.
- Shaw TRD., Duncan FM., Williams BC., Crickton E., Thomson *et al.* Plasma free captopril concentrations during short and long term treatment with oral captopril for heart failure. *British Heart Journal.* 1985; **54**: 160-165
- Shimada K., Tanaka M., Nambara T., Imai Y., Abe K., *et al.* Determination of captopril in human blood by high-performance liquid chromatography with electrochemical detection. *Journal of Chromatography.* 1982; **227**: 445-451.

Singhvi SM., McKinstry DN., Shaw JM., Willard DA., Migdalof BH. Effect of food on the bioavailability of captopril in healthy subjects. *J. Clin Pharmacol.* 1982; **22**: 135-40.

Sloand JA., Izzo Jr. JL. Captopril reduces urinary cystine excretion in cystinuria. *Archives of Internal Medicine* 1987; **147**: 1409-1412.

Stanislaw Sypniewski, Edward Bald. Determination captopril and its disulphides in whole human blood and urine by high-performance liquid chromatography with ultraviolet detection and precolumn derivatization. *Journal of Chromatography A.* 1996; **729**: 335-340.

Steinijans VW., Diletti E. Statistical analysis of bioavailability studies: parametric and nonparametric confidence intervals. *Eur. J. Clin Pharmacol.* 1983; **24**:127-136.

Steinijans VW., Hauschke D. Update on the statistical analysis of bioequivalence studies. *International Journal of Clinical Pharmacology, Therapy and Toxicology.* 1990; **28** (3): 103-110.

Steinijans VW., Sauter R, Jonkman JHG., Schulz HU., Stricker H., Blume H. Bioequivalence studies: single vs. multiple dose. *Int. J. Clin Pharmacol Ther Toxicol.* 1989; **27**: 261-266.

Taguma Y., Kitamoto Y., Futaki G., Ueda H., Monma H. Effect of captopril on heavy proteinuria in azotemic diabetes. *New England journal of Medicine* .1985; **313**: 1617-1620

Tomiharu Ito, Yusuhiko Matsuki, Hiroyuki Kurihara, Toshio Nambara. Sensitive method for determination of captopril in biological fluids by gas chromatography-mass spectrometry. *Journal of Chromatography.*1987; **417**: 79-87.

Unger T., Gohlke P. Converting enzyme inhibitors in cardiovascular therapy: current status and future potential. *Cardiovasc Res.* 1994; **28**: 146 – 58.

- Vernon M. Chinchilli. The assessment of individual and population bioequivalence. *Journal of Biopharmaceutical Statistics*. 1996; **6**: 1-14.
- Vinod Shah. Bioanalytical Methods Validation for Human Studies. Guidance for Industry. *U.S. Department of Health and Human Services Food and Drug Administration*. 1998.
- Westlake WJ. Statistical aspects of comparative bioavailability trials. *Biometrics*. 1979; **35**: 273-280.
- Wieling J., Hendriks G., Tamminga WJ., Hempenius J., Mensink CK., Oosterhuis B., Jonkman JHG. Rational experimental design for bioanalytical methods validation. Illustration using an assay method for total captopril in plasma. *Journal of Chromatography A*. 1996; **730**: 381-394.
- Williams GH., Hollenberg NK., Accentuated vascular and endocrine response to SQ 20,881 in hypertension. *New England Journal of Medicine*. 1977; **297**: 184-188.
- Williams GM., Sugerman AA. The effect of a meal at varying times relative to drug administration, on the bioavailability of captopril. *Journal of Clinical Pharmacology*. 1982; **22**.
- Wong KK., and Dreyfuss J. The invitro metabolism of ³⁵S- captopril (SQ14225) an antihypertensive agent. *Pharmacologist*. 1978; **20**: 213
- Wong KK., Lan SJ., Migdalof BH., In vitro biotransformation ¹⁴C- captopril in the blood of rats, dogs, and humans. *Chemical pharmacology*. 1981; **30**: 2643-2650.
- Zannad F. Trandolapril: how does it differ from other angiotensin-converting enzyme inhibitors? *Drugs*. 1993; **46**(suppl. 2): 172-82.

APPENDICES

LIST OF APPENDICES

APPENDIX A1 GCMS ASSAY FOR CAPTOPRIL	164
A1.1 LABORATORY WORKING MANUAL	165
A1.2 SELECTED GCMS CHROMATOGRAMS OF CAPTOPRIL FROM STANDARD, QC SAMPLES AND SAMPLES	177
APPENDIX A2 BIOEQUIVALENCE STUDY	180
A2.1 INDIVIDUAL PLASMA CONCENTRATION FOR ALL BIOEQUIVALENCE STUDIES	181
A2.2 PAIR WISE PRESENTATION OF INDIVIDUAL PLOT FOR PLASMA CAPTOPRIL CONCENTRATION VERSUS TIME	189
A2.3 UNIVERSITY HOSPITAL MEDICAL ETHICS SUB-COMMITTEE APPROVAL LETTER	212
A2.4 SUBJECT INFORMATION SHEET AND CONSENT FORM	213